MCM
TBPH icon

Moore Capital Management’s Theravance Biopharma TBPH Stock Holding History

Moore Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-40,000
Closed -$924K – 293
2020
Q1 		$924K Sell
40,000
-10,000
-20% -$250K 0.04% 131
2019
Q4 		$1.29M Buy
+50,000
New +$972K 0.04% 200

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moore Capital Management's TBPH Position: Q2 2020 in Review

Moore Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2020, closing a stake of 40,000 shares — an estimated $924K sold.

Moore Capital Management first reported a position in TBPH in Q4 2019 and held it in 2 quarters. The position peaked at $1.29M in Q4 2019. 125 funds tracked by Wall St. Rank hold TBPH as of Q2 2020.

  • Moore Capital Management reported no remaining Theravance Biopharma position as of Q2 2020 after selling out during the quarter.
  • Moore Capital Management sold 40,000 Theravance Biopharma shares in Q2 2020, an estimated $924K.
  • Moore Capital Management first reported a position in Theravance Biopharma in Q4 2019 and held it in 2 quarters.
  • Moore Capital Management's Theravance Biopharma position peaked at $1.29M in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2020.

Based on Moore Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.